Industry Leader Joins Orion Biotechnology Board of Directors
OTTAWA, Canada, Nov. 20, 2018
OTTAWA, Canada, Nov. 20, 2018 /PRNewswire-PRWeb/ -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that it has appointed Theresa Firestone to its Board of Directors. Theresa brings more than 25 years of experience in the pharmaceutical and health care industries, including 15 years of strategic commercial leadership at Pfizer where she had overall responsibility for a P&L of $1.4b.
"We are delighted to welcome Theresa to the Orion board as the company continues to advance its growing pipeline" commented Mr. Rudolf Bom, Chairman of the Board of Directors of Orion. "Theresa's experience and leadership in commercializing pharmaceutical products globally make her an ideal candidate to help Orion navigate the commercial opportunities of our strong pipeline of product candidates".
Ms. Firestone has held senior leadership roles in Pharmaceuticals and Health Care Management, in Canada, Europe and Asia. Theresa was Regional President, Asia Emerging Markets with Pfizer Inc. (Shanghai and HK) where she had overall responsibility for nine emerging markets in Asia. She has also been a Corporate Director for Merus Labs International (TSE: MSL) from 2014-17 and has held board positions with several other organizations including the Canadian Association for Pharmacy Distribution Management. Ms. Firestone is currently Senior Vice President, Healthcare Businesses at Shoppers Drug Mart (SDM). In this role she is responsible for providing overall leadership to several business units within the company including MediSystem Pharmacies, Specialty Health Network, Sanis Health, 43 corporately owned Shoppers Home Healthcare and Wellwise retail outlets, wellwise.ca, and Pharmaceutical Partnerships.
"It's truly an exciting time to be joining Orion Biotechnology" said Ms. Firestone. "The company has an impressive portfolio of product candidates with tremendous commercial potential. I am delighted to be working with the outstanding leadership team to bring these novel best-in-class therapies to market."
"The Board of Directors and I are very pleased to welcome Theresa to the Board" said Mark Groper President and CEO. "She is a proven leader, successful in launching and commercializing new medicines, and building world-class organizations. Theresa's experience will be invaluable to our team, especially as we enter the next critical phase of our growth including initiation of clinical trials. Theresa's leadership and skills in our industry are internationally recognized and we look forward to her contributions to the growth and success of our enterprise."
About Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world's leading research institutions such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. Learn more at http://www.orionbiotechnology.com.
This press release contains forward-looking information, which reflects Orion's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Orion Biotechnology